Publications

Filters (8)
September 19, 2020

3-Years follow-up results of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus Debio 1143 (xevinapant) or placebo in…

Read more
September 17, 2020

Safety and efficacy of Xevinapant (Debio 1143), an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in…

Read more
August 3, 2020

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind,…

Read more
September 24, 2019

Debio 1143 Mode of Action: a Broad Chemo-Radio and Immuno-Therapy Sensitizer

Read more
September 24, 2019

Squamous Cell Carcinoma Of The Head & Neck (SCCHN) – Infographic

Read more
June 1, 2019

A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid…

Read more
April 3, 2019

Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the smac mimetic Debio 1143 in patients…

Read more
December 14, 2018

DEBIO 1143, an IAP inhibitor, reverses ovarian cancer cells carboplatin resistance and triggers apoptotic or necroptotic cell death

Read more
December 2, 2018

Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in…

Read more